Abivax SA ADS/$ABVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abivax SA ADS
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Ticker
$ABVX
Sector
Primary listing
Employees
69
Headquarters
Website
Abivax SA ADS Metrics
BasicAdvanced
$9.8bn
-
-$5.70
-0.10
-
Price and volume
Market cap
$9.8bn
Beta
-0.1
52-week high
$148.83
52-week low
$5.59
Average daily volume
923k
Financial strength
Current ratio
8.747
Quick ratio
8.583
Long term debt to equity
6.764
Total debt to equity
7.05
Interest coverage (TTM)
-8.64%
Profitability
EBITDA (TTM)
-288.749
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-7,354.53%
Operating margin (TTM)
-5,384.14%
Effective tax rate (TTM)
-1.77%
Revenue per employee (TTM)
$82,500
Management effectiveness
Return on assets (TTM)
-38.95%
Return on equity (TTM)
-135.58%
Valuation
Price to revenue (TTM)
1,584.325
Price to book
18.2
Price to tangible book (TTM)
19.26
Price to free cash flow (TTM)
-44.895
Free cash flow yield (TTM)
-2.23%
Free cash flow per share (TTM)
-2.734
Growth
Revenue change (TTM)
-63.22%
Earnings per share change (TTM)
72.93%
3-year revenue growth (CAGR)
0.48%
10-year revenue growth (CAGR)
34.96%
3-year earnings per share growth (CAGR)
14.97%
10-year earnings per share growth (CAGR)
11.42%
Abivax SA ADS News
AllArticlesVideos
Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears
Benzinga·2 months ago
Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC
CNBC·2 months ago
Abivax spokesperson denies takeover rumors reported by French media
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abivax SA ADS stock?
Abivax SA ADS (ABVX) has a market cap of $9.8B as of May 09, 2026.
What is the P/E ratio for Abivax SA ADS stock?
The price to earnings (P/E) ratio for Abivax SA ADS (ABVX) stock is 0 as of May 09, 2026.
Does Abivax SA ADS stock pay dividends?
No, Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders as of May 09, 2026.
When is the next Abivax SA ADS dividend payment date?
Abivax SA ADS (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Abivax SA ADS?
Abivax SA ADS (ABVX) has a beta rating of -0.1. This means that it has an inverse relation to market volatility.